

Additional file 3

Table: Detailed model outputs of Joinpoint regression

Antimicrobial susceptibility	Periods (year)	APC (95% CI)	β	t	P	AAPC (95% CI)	β	t/Z ^a	P
E. coli to ampicillin	2012-2021	-7.5 (-18.7, 5.3)	-0.08	-1.39	0.20	-7.5 (-18.7, 5.3)	-0.08	-1.39	0.20
E. coli to cefepime	2012-2021	-1.6 (-4.6, 1.5)	-0.02	-1.21	0.26	-1.6 (-4.6, 1.5)	-0.02	-1.21	0.26
E. coli to gentamicin	2012-2021	1.2 (-4.3, 7.0)	0.01	0.50	0.63	1.2 (-4.3, 7.0)	0.01	0.50	0.63
E. coli to cefotaxime	2012-2021	0.1 (-4.7, 5.1)	0.0007	0.04	0.97	0.1 (-4.7, 5.1)	0.0007	0.04	0.97
E. coli to ceftriaxone	2012-2021	0.04 (-6.5, 7.0)	0.0004	0.01	0.99	0.04 (-6.5, 7.0)	0.0004	0.01	0.99
E. coli to meropenem	2012-2021	0.0 (-0.0, 0.0)	0.00	NA	NA	0.0 (-0.0, 0.0)	0.00	NA	NA
ESBL-negative E. coli strains ^b	2012-2014	281.3 (34.6, 980.2)	1.34	5.53	0.03 ^c	62.4 (44.3, 82.9)	0.41	8.00	<0.001 ^c
	2014-2018	53.7 (18.4, 99.5)	0.43	7.09	0.02 ^c				
	2018-2021	-1.0 (-9.2, 8.0)	-0.01	-0.48	0.68				
GBS to erythromycin	2012-2021	55.2 (23.2, 95.5)	0.44	4.39	0.002 ^c	55.2 (23.2, 95.5)	0.44	4.39	0.002 ^c
GBS to clindamycin	2012-2016	161.0 (4.3, 553.2)	0.96	2.69	0.04 ^c	54.8 (9.6, 118.6)	0.39	2.50	<0.001 ^c
	2016-2021	1.9 (-28.5, 45.4)	0.02	0.14	0.90				
GBS to linezolid	2012-2021	0.0 (-0.0, 0.0)	0.00	NA	NA	0.0 (-0.0, 0.0)	0.00	NA	NA
GBS to ceftriaxone	2012-2021	0.0 (-0.2, 0.3)	0.0003	0.30	0.77	0.0 (-0.2, 0.3)	0.0003	0.30	0.77
GBS to vancomycin	2012-2021	0.0 (-0.0, 0.0)	0.00	NA	NA	0.0 (-0.0, 0.0)	0.00	NA	NA
E. spp. to ampicillin	2012-2021	-11.7 (-15.2, -8.1)	-0.12	-7.16	<0.001 ^c	-11.7 (-15.2, -8.1)	-0.12	-7.16	<0.001 ^c
E. spp. to linezolid	2012-2021	0.0 (-0.0, 0.0)	0.00	NA	NA	0.0 (-0.0, 0.0)	0.00	NA	NA
E. spp. to penicillin	2012-2021	-2.3 (-7.6, 3.2)	-0.02	-0.997	0.35	-2.3 (-7.6, 3.2)	-0.02	-0.997	0.35
E. spp. to high-concentration gentamicin	2012-2021	0.8 (-6.6, 8.7)	0.01	0.23	0.82	0.8 (-6.6, 8.7)	0.01	0.23	0.82
	2012-2021	0.0 (-0.0, 0.0)	0.00	NA	NA	0.0 (-0.0, 0.0)	0.00	NA	NA
S. aureus to clindamycin	2012-2021	0.9 (-12.1, 15.9)	0.01	0.16	0.88	0.9 (-12.1, 15.9)	0.01	0.16	0.88

Table: Detailed model outputs of Joinpoint regression (continued)

Antimicrobial susceptibility	Periods (year)	APC (95% CI)	β	t	P	AAPC (95% CI)	β	t/Z ^a	P
S. aureus to linezolid	2012-2021	0.0 (-0.0, 0.0)	0.00	NA	NA	0.0 (-0.0, 0.0)	0.00	NA	NA
S. aureus to vancomycin	2012-2021	0.0 (-0.0, 0.0)	0.00	NA	NA	0.0 (-0.0, 0.0)	0.00	NA	NA
S. aureus to penicillin	2012-2018	2.8 (-9.6, 17.0)	0.03	0.56	0.60	56.2 (34.8, 81.0)	0.41	5.90	<0.001 ^c
	2018-2021	260.3 (114.5, 505.2)	1.28	6.35	0.001 ^c				
S. aureus to gentamicin	2012-2021	-0.1 (-0.8, 0.7)	-0.0005	-0.17	0.87	-0.1 (-0.8, 0.7)	-0.0005	-0.17	0.87
S. aureus to oxacillin	2012-2021	-1.1 (-2.4, 0.2)	-0.01	-1.89	0.10	-1.1 (-2.4, 0.2)	-0.01	-1.89	0.10

Abbreviations: APC, annual percentage change; AAPC, average annual percentage change; CI, confidence intervals; ESBL, extended-spectrum beta-lactamase; E. coli, Escherichia coli; GBS, Group B Streptococcus; E. spp., Enterococcus spp.; S. aureus, Staphylococcus aureus; NA, not available.

^a If the AAPC is within one segment, the t-distribution is used. Otherwise, the normal (Z) distribution is used.

^b Proportion of ESBL-negative E. coli strains.

^c P < 0.05.